ES2594856T3 - Inhibidores de IAP - Google Patents

Inhibidores de IAP Download PDF

Info

Publication number
ES2594856T3
ES2594856T3 ES13733613.7T ES13733613T ES2594856T3 ES 2594856 T3 ES2594856 T3 ES 2594856T3 ES 13733613 T ES13733613 T ES 13733613T ES 2594856 T3 ES2594856 T3 ES 2594856T3
Authority
ES
Spain
Prior art keywords
carcinoma
compounds
mmol
acid
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13733613.7T
Other languages
English (en)
Spanish (es)
Inventor
Frederick Cohen
John A. Flygare
Lewis J. Gazzard
Vickie Hsiao-Wei Tsui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Curis Inc
Original Assignee
Genentech Inc
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Curis Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2594856T3 publication Critical patent/ES2594856T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ES13733613.7T 2012-01-03 2013-01-03 Inhibidores de IAP Active ES2594856T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261582760P 2012-01-03 2012-01-03
US201261582760P 2012-01-03
PCT/US2013/020124 WO2013103703A1 (en) 2012-01-03 2013-01-03 Inhibitors of iap

Publications (1)

Publication Number Publication Date
ES2594856T3 true ES2594856T3 (es) 2016-12-23

Family

ID=48695302

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13733613.7T Active ES2594856T3 (es) 2012-01-03 2013-01-03 Inhibidores de IAP
ES16189661.8T Active ES2672809T3 (es) 2012-01-03 2013-01-03 Inhibidores de IAP

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16189661.8T Active ES2672809T3 (es) 2012-01-03 2013-01-03 Inhibidores de IAP

Country Status (41)

Country Link
US (6) US8716236B2 (OSRAM)
EP (2) EP3133073B1 (OSRAM)
JP (2) JP5747137B2 (OSRAM)
KR (3) KR101553792B1 (OSRAM)
CN (2) CN104159897A (OSRAM)
AR (2) AR089623A1 (OSRAM)
AU (1) AU2013202780B2 (OSRAM)
BR (1) BR112014016637B1 (OSRAM)
CA (1) CA2861637C (OSRAM)
CL (1) CL2014001770A1 (OSRAM)
CO (1) CO7020915A2 (OSRAM)
CR (1) CR20140367A (OSRAM)
CY (2) CY1118371T1 (OSRAM)
DK (2) DK3133073T3 (OSRAM)
EC (1) ECSP14011792A (OSRAM)
ES (2) ES2594856T3 (OSRAM)
HK (1) HK1203949A1 (OSRAM)
HR (2) HRP20161381T1 (OSRAM)
HU (2) HUE037760T2 (OSRAM)
IL (2) IL242314A (OSRAM)
LT (2) LT2800749T (OSRAM)
MA (1) MA35895B1 (OSRAM)
ME (2) ME02526B (OSRAM)
MX (1) MX336294B (OSRAM)
MY (1) MY178390A (OSRAM)
NO (1) NO2755614T3 (OSRAM)
NZ (1) NZ627480A (OSRAM)
PE (1) PE20142182A1 (OSRAM)
PH (2) PH12014501534B1 (OSRAM)
PL (2) PL2800749T3 (OSRAM)
PT (2) PT3133073T (OSRAM)
RS (2) RS55327B1 (OSRAM)
RU (2) RU2728789C2 (OSRAM)
SG (1) SG11201403784QA (OSRAM)
SI (2) SI2800749T1 (OSRAM)
SM (2) SMT201800352T1 (OSRAM)
TR (1) TR201808088T4 (OSRAM)
TW (1) TWI503318B (OSRAM)
UA (1) UA114417C2 (OSRAM)
WO (1) WO2013103703A1 (OSRAM)
ZA (1) ZA201405535B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2755614T3 (OSRAM) 2012-01-03 2018-03-31
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用
IL274598B2 (en) 2017-11-13 2025-01-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd SMAC mimetics used as IAP inhibitors and their use
CN112533898A (zh) 2018-07-31 2021-03-19 日商泛美克斯股份有限公司 杂环化合物
US20220402935A1 (en) 2019-07-31 2022-12-22 Fimecs, Inc. Heterocyclic compound
US20230029259A1 (en) * 2019-12-02 2023-01-26 Ascentage Pharma (Suzhou) Co., Ltd. Combination of iap inhibitors and parp or mek inhibitors or other chemotherapeutic agents
EP4093394A1 (en) 2020-01-20 2022-11-30 Astrazeneca AB Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
AU2022463015A1 (en) 2021-10-22 2024-05-09 Tract Pharmaceuticals, Inc. Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues
CN117110469B (zh) * 2023-08-18 2025-12-09 中国检验检疫科学研究院 一种测定防脱发类化妆品中禁用组分的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE69830577T2 (de) 1997-04-15 2006-05-04 Genentech, Inc., South San Francisco Halo-alkoxycarbonylverbindungen
CA2570321C (en) * 2004-07-02 2013-10-08 Genentech, Inc. Inhibitors of iap
KR20120127754A (ko) * 2004-12-20 2012-11-23 제넨테크, 인크. Iap의 피롤리딘 억제제
US8044209B2 (en) 2006-10-12 2011-10-25 Novartis Ag Pyrrolydine derivatives as IAP inhibitors
NZ598890A (en) 2007-04-30 2013-10-25 Genentech Inc Inhibitors of iap
NO2755614T3 (OSRAM) * 2012-01-03 2018-03-31
USD690416S1 (en) 2012-12-12 2013-09-24 Pharmajet, Inc. Needle-free syringe

Also Published As

Publication number Publication date
BR112014016637A2 (pt) 2017-06-13
CL2014001770A1 (es) 2015-04-17
UA114417C2 (uk) 2017-06-12
EP3133073B1 (en) 2018-05-02
EP3133073A3 (en) 2017-03-22
ME03084B (me) 2019-01-20
HK1203949A1 (en) 2015-11-06
EP2800749B1 (en) 2016-09-21
RU2728789C2 (ru) 2020-07-31
PT2800749T (pt) 2016-10-24
DK2800749T3 (en) 2016-11-07
HUE037760T2 (hu) 2018-09-28
NO2755614T3 (OSRAM) 2018-03-31
ME02526B (me) 2017-02-20
KR101553792B1 (ko) 2015-09-16
KR20180051646A (ko) 2018-05-16
MA35895B1 (fr) 2014-12-01
PH12014501534A1 (en) 2014-10-08
US9586991B2 (en) 2017-03-07
RU2016124658A (ru) 2018-12-04
PE20142182A1 (es) 2015-01-16
CA2861637C (en) 2017-07-18
TR201808088T4 (tr) 2018-06-21
LT3133073T (lt) 2018-06-25
CN104159897A (zh) 2014-11-19
JP5747137B2 (ja) 2015-07-08
RU2593259C2 (ru) 2016-08-10
KR20140107670A (ko) 2014-09-04
PH12015501038B1 (en) 2015-09-21
US11963994B2 (en) 2024-04-23
HRP20180976T1 (hr) 2018-08-10
US20160102119A1 (en) 2016-04-14
EP3133073A2 (en) 2017-02-22
MX2014007895A (es) 2015-03-19
US20170136084A1 (en) 2017-05-18
US20220211797A1 (en) 2022-07-07
JP2015504072A (ja) 2015-02-05
AR089623A1 (es) 2014-09-03
BR112014016637B1 (pt) 2022-06-14
US9238675B2 (en) 2016-01-19
ZA201405535B (en) 2017-08-30
RS55327B1 (sr) 2017-03-31
PL3133073T3 (pl) 2018-09-28
US11096982B2 (en) 2021-08-24
BR112014016637A8 (pt) 2017-07-04
RU2016124658A3 (OSRAM) 2019-09-09
US20190224269A1 (en) 2019-07-25
MY178390A (en) 2020-10-12
NZ627480A (en) 2016-04-29
KR101917992B1 (ko) 2018-11-13
CY1118371T1 (el) 2017-06-28
CY1120355T1 (el) 2019-07-10
CR20140367A (es) 2015-02-18
US8716236B2 (en) 2014-05-06
HRP20161381T1 (hr) 2016-12-02
EP2800749A1 (en) 2014-11-12
MX336294B (es) 2016-01-14
CO7020915A2 (es) 2014-08-11
ES2672809T3 (es) 2018-06-18
CN107915728A (zh) 2018-04-17
CA2861637A1 (en) 2013-07-11
PT3133073T (pt) 2018-06-18
US20140235551A1 (en) 2014-08-21
DK3133073T3 (en) 2018-06-18
SG11201403784QA (en) 2014-08-28
AU2013202780B2 (en) 2015-04-16
US20130172264A1 (en) 2013-07-04
TW201333001A (zh) 2013-08-16
CN107915728B (zh) 2021-04-30
RS57438B1 (sr) 2018-09-28
KR20150065960A (ko) 2015-06-15
KR101855566B1 (ko) 2018-05-04
EP2800749A4 (en) 2015-08-05
SMT201600357B (it) 2016-11-10
SI2800749T1 (sl) 2016-11-30
AR123542A2 (es) 2022-12-14
TWI503318B (zh) 2015-10-11
WO2013103703A1 (en) 2013-07-11
IL242314A (en) 2016-08-31
SMT201800352T1 (it) 2018-09-13
HUE031305T2 (hu) 2017-07-28
RU2014130171A (ru) 2016-02-27
PL2800749T3 (pl) 2017-01-31
AU2013202780A1 (en) 2013-07-18
IL233386A0 (en) 2014-08-31
JP2015199738A (ja) 2015-11-12
LT2800749T (lt) 2016-10-25
PH12015501038A1 (en) 2015-09-21
IL233386A (en) 2016-08-31
PH12014501534B1 (en) 2014-10-08
ECSP14011792A (es) 2015-12-31
SI3133073T1 (en) 2018-06-29

Similar Documents

Publication Publication Date Title
US11963994B2 (en) Inhibitors of IAP
HK1253823B (zh) Iap抑制剂
HK1253823A1 (en) Inhibitors of iap
AU2015203844A1 (en) Inhibitors of IAP
HK1234396A1 (en) Inhibitors of iap
HK1234396B (en) Inhibitors of iap